The Life Raft Group had the pleasure of hosting the global New Horizons GIST meeting this year in our Wayne, New Jersey office. This international meeting traditionally gathers global GIST advocates with the shared [...]
The Life Raft Group and UCSD hosted a three-day event at University of California, San Diego UCSD-Moores Cancer Center from July 13th through July 15th. A GIST Awareness Day (GAD) event took place on July [...]
On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time [...]
Drs. Breelyn Wilky, Jonathan Trent, AlanLivingstone, and Pablo Bejarano show off theirrare in Miami. The 2015 GIST Days of Learning Tour continues to be successful. A GIST Day of Learning (GDOL) is a free, [...]
GIST advocates from around the world gathered in Miami for the annual New Horizons conference. This international meeting was launched by Novartis Oncology in 2003 with the title, “New Horizons in Treating CML and GIST,” [...]
You may have noticed a new look for Gleevec when you refilled your 400-mg prescription.Novartis has introduced new packaging in the U.S. market that includes each individual tablet in a blister pack. This is designed [...]
Mo Collins Are you interested in learning about how others live with GIST? Do you have questions about patient assistance programs, treatment options and the nutritional and emotional aspects of GIST? Join us [...]
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
Family planning can be one of the hardest decisions patients with GIST make, but for Carolina Ponce Williams the decision was easy. At high risk for progression, Carolina longed to start a family. So she decided to adopt.
Dan Vaella was instrumental in getting Gleevec to market. After 25 years at Novartis and Sandoz, he has chosen to step down as Chairman.